CTV News |
Novel Biologic Promising for Allergic Asthma
MedPage Today SAN DIEGO — A novel first-in-class biologic agent targeting allergic inflammation appeared promising for allergen-induced asthma in a phase IIb trial. AMG 157, an anti-thymic stromal lymphopoietin (TSLP) humanized monoclonal antibody, reduced most … Researchers discover new potential antibody treatment for asthma Canadian study finds potential antibody treatment for mild asthma Hamilton researchers discover potential asthma treatment |
View full post on asthma – Google News